Status on domestic clinical trials of chimeric antigen receptor T cell therapy products containing B-cell receptor-related protein CD19
10.13699/j.cnki.1001-6821.2024.19.030
- VernacularTitle:含靶向B细胞受体相关蛋白CD19的嵌合抗原受体T细胞治疗产品国内临床试验现状
- Author:
Min LIU
1
;
Yan CHEN
;
Wen-Ya TANG
;
Feng XUE
;
Hai-Xue WANG
Author Information
1. 国家药品监督管理局 药品审评中心,北京 102600
- Keywords:
chimeric antigen receptor T cell;
cell therapy;
clinical trials;
B-cell receptor-related protein CD19
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(19):2909-2912
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,chimeric antigen receptor T cell(CAR-T)therapeutic products have shown good efficacy in the treatment of blood tumors,and breakthroughs have also been made in the treatment of solid tumors and autoimmune diseases.In order to further understand the clinical research and development progress of CAR-T products,this paper mainly uses the drug clinical trial registration and information publication platform of the Center for Drug Evaluation National Medical Products Administration as the information source,and focuses on the statistical analysis of the clinical trial progress of domestic CAR-T cell therapy products containing the targeted B-cell receptor-related protein CD19.It is hoped to further improve the quality and efficiency of clinical research and development of CAR-T cell therapy products,strengthen the sponsor's awareness of main responsibility,and timely update trial information to protect the rights and interests of subjects during clinical trials.
